Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)-Reference-Cited by-同舟云学术

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

Published:2023-08-15 Issue:4 Volume:208 Page:406-416
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Anzueto Antonio¹²,Barjaktarevic Igor Z.³^ORCID,Siler Thomas M.⁴^ORCID,Rheault Tara⁵,Bengtsson Thomas⁶,Rickard Kathleen⁵,Sciurba Frank⁷^ORCID

Affiliation:

1. South Texas Veterans Health Care System, San Antonio, Texas;

2. University of Texas Health, San Antonio, Texas;

3. Division of Pulmonary and Critical Care, University of California, Los Angeles, Los Angeles, California;

4. Midwest Chest Consultants, PC, St. Charles, Missouri;

5. Verona Pharma, Inc., Raleigh, North Carolina;

6. StatMind AB, Lund, Sweden; and

7. Division of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania

Funder

Verona Pharma plc

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202306-0944OC

Reference50 articles.

1. The unmet global burden of COPD

2. Symptomatic burden of COPD for patients receiving dual or triple therapy

3. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ensifentrine approval: A milestone in the treatment of COPD;Pulmonary Pharmacology & Therapeutics;2024-12

2. New Therapies in Outpatient Pulmonary Medicine;Medical Clinics of North America;2024-09

3. Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease;Trends in Pharmacological Sciences;2024-09

4. Ensifentrine: First Approval;Drugs;2024-08-28

5. Inhalational Drug Devices: Revisiting the Linchpin of Asthma Management;Journal of Personalized Medicine;2024-08-16